PRESS RELEASE: NRG-RTOG 0525 in JAMA Oncology

NRG Oncology Researchers Develop Improved Model to Predict Glioblastoma Patients’ Response to Radiation Temozolomide Chemotherapy

A secondary analysis of the clinical trial NRG-RTOG 0525 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients with Newly Diagnosed Glioblastoma or Gliosarcoma was initiated to refine the existing, clinically-based partitioning analysis (RPA) model by incorporating molecular variables. The results of this analysis were published in the Journal of the American Medical Association (JAMA) Oncology on January 12, 2017.


Read the full press release





View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Unsubscribe